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Educational Programs Are Needed
Johannes Ring
Anaphylaxis is the number one emergency situation in allergy. More than 100 yearsafter its ﬁrst description, there are still many problems and open questions regarding
pathophysiology, diagnosis, treatment, and prevention. Many national and international
societies have edited guidelines that give clear recommendations for acute treatment,
showing algorithms depending on the severity of the clinical symptomatology, which can
be graded rather simply.1 Adrenaline has been shown to be the most important drug to
be applied, and the intramuscular route has a clear-cut advantage over other ways of
administration in the initial phase. Recently, the World Allergy Organization has published
a position statement on epinephrine application as a World Allergy Organization Report.2
Although things seem pretty clear at a superﬁcial glance, there are some controver-
sies in detail with regard to when in the very early stage of anaphylaxis adrenaline should
be given. There seems to be a divergence between pediatric allergists and allergists deal-
ing more and mostly with adult patients because adrenaline has well-known pharmaco-
logical effects that can be detrimental to people with severe cardiac disease, especially
arrhythmia. Furthermore, problems arise in prophylactic use, which means giving anti-
anaphylactic treatment before development of symptoms after exposure to a known al-
lergen. The situation is simple when it is a child who has inadvertently eaten peanuts and
a history of severe peanut anaphylaxis.
The situation becomes more complex if a patient who had experienced an ana-
phylactic reaction in the past to an ubiquitous food such as cow’s milk or hen’s egg develops
a feeling of uneasiness without clear-cut anaphylactic symptomatology and without
knowing whether he has been exposed to the relevant allergen. This is even more important
in patients in whom psychosomatic interaction plays a role and who may react in the
direction of panic-fear attacks together with immunoglobulin EYmediated allergy. In these
patients, coping with the anxiety is a major issue.
Although the use of adrenaline autoinjectors is simple and there is ample informa-
tion with regard to correct application and a multitude of leaﬂets, it is surprising to see
how often patients do not understand andVif they have understoodVtend to forget the
correct use of these devices. This phenomenon shows a surprising lack of relation to the
intelligence quotient of the individual. Even doctors all of a sudden inject the adrenaline
into their ﬁngers when trying to handle the tools!
Therefore, in the management of patients with a history of anaphylaxis, it is crucial
to communicate the information and the motivation to learn to the patients. This can best
be achieved by structured educational programs. There is a long story of success concern-
ing educational programs for asthma and eczema, where even controlled trials have been
performed and proven the efﬁcacy.3 Similar programs have to be developed for anaphy-
laxis. In Germany, a working group named Anaphylaxis: Training and Education (acro-
nym, AGATE) was founded recently that develops a structured educational program for
Banaphylaxis schools,[ which will be studied in a controlled trial and hopefully imple-
mented in Germany. Other countries are on the way to similar activities.
As old and historic as anaphylaxis may sound and as clear as pathophysiology and
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